<DOC>
	<DOCNO>NCT01164579</DOCNO>
	<brief_summary>Evaluation efficacy safety tofacitinib ( CP-690,550 ) treatment early rheumatoid arthritis adult patient moderate severe disease methotrexate na√Øve . The efficacy evaluate explore effect joint structure assess magnetic resonance imaging , x-rays standard clinical assessment .</brief_summary>
	<brief_title>Effects Tofacitinib ( CP-690,550 ) Magnetic Resonance Imaging ( MRI ) - Assessed Joint Structure In Early Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Adult patient moderate severe early rheumatoid arthritis ( &lt; 2 year ) methotrexate biologic disease modify antirheumatic drug naive . Pregnant lactating patient ; Patients renal hepatic impairment severe progress disease ; Patients contraindication magnetic resonance image gadolinium contrast .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Early Rheumatoid Arthritis</keyword>
	<keyword>Joint Structure</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Janus Kinase ( JAK ) Inhibitor</keyword>
	<keyword>Tasocitinib</keyword>
	<keyword>Tofacitinib</keyword>
</DOC>